CCAR1 Antibody - BSA Free

Western Blot: CCAR1 Antibody [NB500-186]

Western Blot: CCAR1 Antibody [NB500-186] - Detection of Human CCAR1on HeLa whole cell lysate using NB500-186. CCAR1 was also IPed with another rabbit anti-CCAR1 antibody, NB500-187, and NB500-188. IPed CCAR1 was blotted using NB500-188.

Western Blot: CCAR1 Antibody [NB500-186]

Western Blot: CCAR1 Antibody [NB500-186] - Detection of Human and Mouse CCAR1 by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, Jurkat, mouse TCMK-1, and mouse NIH3T3 cells. Antibodies: Affinity purified rabbit anti-CCAR1 antibody NB500-186 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 10 seconds.

Western Blot: CCAR1 Antibody [NB500-186]

CCAR1-Antibody-Western-Blot-NB500-186-img0008.jpg

Western Blot: CCAR1 Antibody [NB500-186]

CCAR1-Antibody-Western-Blot-NB500-186-img0009.jpg

Immunocytochemistry/ Immunofluorescence: CCAR1 Antibody [NB500-186]

CCAR1-Antibody-Immunocytochemistry-Immunofluorescence-NB500-186-img0012.jpg

Immunoprecipitation: CCAR1 Antibody [NB500-186]

Immunoprecipitation: CCAR1 Antibody [NB500-186] - Detection of human CCAR1 by western blot of immunoprecipitates. Samples: Whole cell lysate (1 mg for IP; 20% of IP loaded) from HeLa cells. Antibodies: Affinity purified rabbit anti-CCAR1 antibody NB500-186 (lot NB500-186-2) used for IP at 6 ug/mg lysate. CCAR1 was also immunoprecipitated by a previous lot (lot NB500-186-1) of the antibody. For blotting immunoprecipitated CCAR1, NB500-186 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 10 seconds.

Western Blot: CCAR1 Antibody [NB500-186] -

Western Blot: CCAR1 Antibody [NB500-186] - Autoantibody discovery in anti–TIF1-gamma –positive DM patients without cancer.(A) Immunoprecipitations (IPs) were performed using lysates made from radiolabeled cells & plasma from anti–TIF1-gamma –positive DM patients, 5 of whom did not have a cancer, & 5 of whom had a detected cancer. An IP performed with a sample from a healthy control (HC) individual is shown in the right-most lane. Migration of molecular weight standards is marked on the left. (B) Immunoblotted lysates. Lysates made from HeLa & A431 cells were immunoblotted with commercial antibodies against TIF1-gamma & CCAR1, as described in the Methods section. Both proteins migrate at approximately 150 kDa. (C) Interaction between CCAR1 & TIF1-gamma. Co-IPs were performed as described in the Methods section, using antibodies against CCAR1 (upper panel, 2 left lanes) or TIF1-gamma (lower panel, 2 left lanes). Detection of the IPs was performed by immunoblotting with anti–TIF1-gamma (upper panel, 2 left lanes) or anti-CCAR1 (lower panel, 2 left lanes) antibodies. Control IPs, performed using Protein A beads only, were performed & immunoblotted as above. IPs were performed in duplicate. These data are representative of those obtained in 2 additional experiments. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35040440), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: CCAR1 Antibody [NB500-186] -

Western Blot: CCAR1 Antibody [NB500-186] - Autoantibody discovery in anti–TIF1-gamma –positive DM patients without cancer.(A) Immunoprecipitations (IPs) were performed using lysates made from radiolabeled cells & plasma from anti–TIF1-gamma –positive DM patients, 5 of whom did not have a cancer, & 5 of whom had a detected cancer. An IP performed with a sample from a healthy control (HC) individual is shown in the right-most lane. Migration of molecular weight standards is marked on the left. (B) Immunoblotted lysates. Lysates made from HeLa & A431 cells were immunoblotted with commercial antibodies against TIF1-gamma & CCAR1, as described in the Methods section. Both proteins migrate at approximately 150 kDa. (C) Interaction between CCAR1 & TIF1-gamma. Co-IPs were performed as described in the Methods section, using antibodies against CCAR1 (upper panel, 2 left lanes) or TIF1-gamma (lower panel, 2 left lanes). Detection of the IPs was performed by immunoblotting with anti–TIF1-gamma (upper panel, 2 left lanes) or anti-CCAR1 (lower panel, 2 left lanes) antibodies. Control IPs, performed using Protein A beads only, were performed & immunoblotted as above. IPs were performed in duplicate. These data are representative of those obtained in 2 additional experiments. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/35040440), licensed under a CC-BY license. Not internally tested by Novus Biologicals.